Jos Jonkers

Cytowane przez

	Wszystkie	Od 2020
Cytowania	44194	21738
h-indeks	100	67
i10-indeks	248	203

4900

2450

1225

3675

2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025125 240 236 273 331 305 455 541 715 1006 1145 1336 1453 1389 1743 2204 2469 2801 3135 3990 4830 4353 4107 3869 578

Dostęp publiczny

Wyświetl wszystko

164 artykuły

12 artykułów

dostępne

niedostępne

Objęte finansowaniem

Współautorzy

Lodewyk WesselsProfessor of Computational Cancer BiologyZweryfikowany adres z nki.nl
de Visser Karin. EProfessor at the LUMC, group leader at the Netherlands Cancer Institute and Oncode InstituteZweryfikowany adres z nki.nl
Sjoerd KlarenbeekVeterinary pathologist, Royal GD Animal HealthZweryfikowany adres z gddiergezondheid.nl
Patrick WB DerksenProfessor of Oncology @ UMC UtrechtZweryfikowany adres z umcutrecht.nl
Jelle WesselingGroup Leader, Netherlands Cancer InstituteZweryfikowany adres z nki.nl
Henne HolstegeAmsterdam UMC, Alzheimer Center, Clinical GeneticsZweryfikowany adres z vumc.nl
Mark J O'ConnorAstraZeneca Oncology UKZweryfikowany adres z astrazeneca.com
Christiaan KlijnVP, Head of Discovery Data Science and Target Discovery, GenmabZweryfikowany adres z genmab.com
Kelly KerstenAssistant Professor at Sanford Burnham Prebys Medical Discovery InstituteZweryfikowany adres z sbpdiscovery.org
Seth B. Coffelt, Ph.D.University of Glasgow/CRUK Beatson InstituteZweryfikowany adres z glasgow.ac.uk
Catrin LutzNetherlands Cancer InstituteZweryfikowany adres z nki.nl
Carlos CaldasUniversity of CambridgeZweryfikowany adres z cruk.cam.ac.uk
Shridar GanesanProfessor of Medicine, Rutgers Cancer Institute of New JerseyZweryfikowany adres z cinj.rutgers.edu
Olaf van TellingenNetherlands Cancer InstituteZweryfikowany adres z nki.nl
Steven de JongProfessor of Preclinical and Translational Oncology, University Medical Center GroningenZweryfikowany adres z umcg.nl
Robert B ClarkeProfessor of Breast Biology, University of ManchesterZweryfikowany adres z manchester.ac.uk
Sabine LinnProfessor of Translational Oncology - Utrecht University; Group leader NKI AmsterdamZweryfikowany adres z nki.nl
S. Nik-ZainalUniversity of CambridgeZweryfikowany adres z cam.ac.uk
Manuel HidalgoWeill Cornell MedicineZweryfikowany adres z med.cornell.edu
Andrew BiankinRegius Professor of Surgery, University of GlasgowZweryfikowany adres z glasgow.ac.uk

Obserwuj

Jos Jonkers

Professor at Leiden University and group leader at Netherlands Cancer Institute, Oncode Institute

Zweryfikowany adres z nki.nl - Strona główna

Mouse Models of Human Cancer Breast Cancer Therapy Resistance BRCA1 BRCA2


Tytuł Sortuj wg cytatów Sortuj wg roku Sortuj wg tytułu	Cytowane przez Cytowane przez	Rok
Landscape of somatic mutations in 560 breast cancer whole-genome sequences S Nik-Zainal, H Davies, J Staaf, M Ramakrishna, D Glodzik, X Zou, ... Nature 534 (7605), 47-54, 2016	2366	2016
Patient-derived xenograft models: an emerging platform for translational cancer research M Hidalgo, F Amant, AV Biankin, E Budinská, AT Byrne, C Caldas, ... Cancer discovery 4 (9), 998-1013, 2014	1779	2014
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis SB Coffelt, K Kersten, CW Doornebal, J Weiden, K Vrijland, CS Hau, ... Nature 522 (7556), 345-348, 2015	1764	2015
Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer J Jonkers, R Meuwissen, H van der Gulden, H Peterse, M van der Valk, ... Nature genetics 29 (4), 418-425, 2001	1193	2001
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs S Rottenberg, JE Jaspers, A Kersbergen, E van der Burg, AOH Nygren, ... Proceedings of the National Academy of Sciences 105 (44), 17079-17084, 2008	1157	2008
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers P Bouwman, A Aly, JM Escandell, M Pieterse, J Bartkova, ... Nature structural & molecular biology 17 (6), 688-695, 2010	1116	2010
Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum S Marino, M Vooijs, H Van Der Gulden, J Jonkers, A Berns Genes & development 14 (8), 994-1004, 2000	981	2000
Replication fork stability confers chemoresistance in BRCA-deficient cells A Ray Chaudhuri, E Callen, X Ding, E Gogola, AA Duarte, JE Lee, ... Nature 535 (7612), 382-387, 2016	924	2016
Long‐term expanding human airway organoids for disease modeling N Sachs, A Papaspyropoulos, DD Zomer‐van Ommen, I Heo, L Böttinger, ... The EMBO journal 38 (4), e100300, 2019	916	2019
Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways MC Boelens, TJ Wu, BY Nabet, B Xu, Y Qiu, T Yoon, DJ Azzam, ... Cell 159 (3), 499-513, 2014	858	2014
Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells A Loonstra, M Vooijs, HB Beverloo, BA Allak, E van Drunen, R Kanaar, ... Proceedings of the National Academy of Sciences 98 (16), 9209-9214, 2001	753	2001
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance P Bouwman, J Jonkers Nature Reviews Cancer 12 (9), 587-598, 2012	721	2012
Interrogating open issues in cancer precision medicine with patient-derived xenografts AT Byrne, DG Alférez, F Amant, D Annibali, J Arribas, AV Biankin, A Bruna, ... Nature Reviews Cancer 17 (4), 254-268, 2017	720	2017
Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis PWB Derksen, X Liu, F Saridin, H van der Gulden, J Zevenhoven, B Evers, ... Cancer cell 10 (5), 437-449, 2006	719	2006
Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development LA Van Meeteren, P Ruurs, C Stortelers, P Bouwman, MA van Rooijen, ... Molecular and cellular biology, 2006	663	2006
REV7 counteracts DNA double-strand break resection and affects PARP inhibition G Xu, JR Chapman, I Brandsma, J Yuan, M Mistrik, P Bouwman, ... Nature 521 (7553), 541-544, 2015	629	2015
The shieldin complex mediates 53BP1-dependent DNA repair SM Noordermeer, S Adam, D Setiaputra, M Barazas, SJ Pettitt, AK Ling, ... Nature 560 (7716), 117-121, 2018	615	2018
PARP Inhibitor Efficacy Depends on CD8⁺ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer C Pantelidou, O Sonzogni, M De Oliveria Taveira, AK Mehta, A Kothari, ... Cancer discovery 9 (6), 722-737, 2019	583	2019
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors JE Jaspers, A Kersbergen, U Boon, W Sol, L Van Deemter, SA Zander, ... Cancer discovery 3 (1), 68-81, 2013	570	2013
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer X Liu, H Holstege, H van der Gulden, M Treur-Mulder, J Zevenhoven, ... Proceedings of the National Academy of Sciences 104 (29), 12111-12116, 2007	540	2007

Nie można teraz wykonać tej operacji. Spróbuj ponownie później.

Prace 1–20

Cytowania rocznie

Powielone cytowania

Scalone cytowania

Dodaj współautorówWspółautorzy

Obserwuj

Cytowane przez

Współautorzy